Phenobarbital embryopathy

Phenobarbital embryopathy, also known as fetal barbiturate syndrome or barbiturate embryopathy, is a rare congenital condition caused by prenatal exposure to phenobarbital, an anticonvulsant medication commonly used to treat epilepsy. When taken during pregnancy, phenobarbital can act as a teratogen, disrupting normal fetal development and leading to a characteristic pattern of birth defects. The condition primarily affects craniofacial development, the central nervous system, and skeletal structures. Key clinical features include craniofacial dysmorphism such as a broad and flat nasal bridge, short nose, hypertelorism (widely spaced eyes), epicanthal folds, wide mouth, and a thin upper lip. Affected individuals may also present with digital anomalies including nail and distal phalanx hypoplasia, growth retardation (both prenatal and postnatal), microcephaly, and developmental delay or intellectual disability of variable severity. Cardiac malformations and other organ anomalies have also been reported in some cases. There is no specific cure or targeted treatment for phenobarbital embryopathy. Management is supportive and multidisciplinary, addressing individual symptoms as they arise. This may include developmental and educational support for cognitive delays, surgical correction of structural anomalies when indicated, and regular monitoring of growth and neurological development. Prevention is the most important strategy, involving careful risk-benefit assessment of anticonvulsant therapy during pregnancy and, when possible, substitution with less teratogenic alternatives under close medical supervision.

Common questions about Phenobarbital embryopathy